Chemotherapy News and Research

Latest Chemotherapy News and Research

CPF proclaims September as 'Pulmonary Fibrosis Awareness Month'

The Coalition for Pulmonary Fibrosis (CPF) announced today the month of September 2012 will be proclaimed "Pulmonary Fibrosis Awareness Month." In previous years, the CPF has celebrated "National Pulmonary Fibrosis Awareness Week" for one week each September, but expanding the time frame to a month will help achieve greater national awareness and fundraising in the race to find treatment and a cure.

7 Apr 2012

State roundup: Health costs cloud forecast for state budgets; Minnesota to use HMO refund on personal care

U.S. state and local governments' fiscal situations have improved recently but will still deteriorate through 2060, the Government Accountability Office said on Thursday. ... The outlook remains gloomy for the future, with healthcare costs, both for public employees and for the Medicaid insurance program for the poor, swelling and weighing on budgets, GAO said.

7 Apr 2012

Research on how cells cope with stress could lead to more effective cancer treatment

Both radiation and many forms of chemotherapy try to kill tumors by causing oxidative stress in cancer cells. New research from USC on a protein that protects cancer and other cells from these stresses could one day help doctors to break down cancer cells' defenses, making them more susceptible to treatment.

7 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

TJUH medical oncologist to receive ASCO Humanitarian Award

Edith Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center (KCC) and Clinical Professor of Medicine and Medical Oncology in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, has been named the 2012 recipient of the American Society of Clinical Oncology (ASCO) Humanitarian Award for her personification of the society's mission and values, and for going above and beyond the call of duty in providing outstanding patient care.

6 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Delcath’s second generation CHEMOSAT system receives European CE Mark

Delcath Systems, Inc. today announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

6 Apr 2012

Uterine cancer up by 43% in UK over last two decades

Figures show that the number of diagnoses remained static for many years, but has increased by 43% since the 1990s. As the number of womb cancer cases have increased over the last decade, so have the number of womb cancer deaths. However, survival has also improved during that period, with 77% of women who are diagnosed with womb cancer now surviving for five years or more.

5 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

First Edition: April 5, 2012

In today's headlines, reports about how the budget debate is mixing into presidential poiltics.

5 Apr 2012

Novel approach to kill acute lymphoblastic leukemia cells

Nora Heisterkamp, PhD, and Reshmi Parameswaran, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, have found a novel approach to killing acute lymphoblastic leukemia (ALL) cells. Using a fusion toxin that specifically targets cancer cells, this novel therapeutic may offer a future alternative to patients who become resistant to chemotherapy.

5 Apr 2012

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine.

5 Apr 2012

Physician groups identify unnecessary procedures

The list of 45 tests and procedures was pulled together by nine medical speciality groups to help reduce spending and improve patients' health.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

ASN participates in ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies, and Consumer Reports in the new Choosing Wisely campaign that helps health care professionals and patients avoid wasteful and sometimes harmful medical interventions.

5 Apr 2012

New cell and animal model of IBC

Inflammatory breast cancer (IBC) is a very aggressive, often misunderstood type of cancer that is diagnosed more frequently in younger women compared with other types of breast cancer. The five-year survival rate is between 25 and 50 percent-significantly lower than the survival rate for other types of breast cancer. The reason for the poor prognosis is that IBC usually grows rapidly and often spreads quickly to other parts of the body, including the brain, bone and lymph nodes.

5 Apr 2012

Uterine cancer deaths rise 20% in the last decade

Deaths from womb (uterine) cancer have risen by nearly twenty per cent in the last decade, according to new figures from Cancer Research UK today.

5 Apr 2012

Feinstein scientists to present three GBM abstracts at AACR annual meeting

Scientists from the Feinstein Institute for Medical Research will present three abstracts about Glioblastoma multiforme (GBM), the most common and deadly adult brain cancer, at the American Association for Cancer Research (AACR) Annual Meeting to be held from Saturday through Wednesday (March 31- April 4) in Chicago, IL.

5 Apr 2012

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.

4 Apr 2012

Study: Functional link between two major causes of treatment failure in breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows a functional link between two major causes of treatment failure in breast cancer, showing the protein behind one of these causes plays a role in increasing the drug resistance properties of the other.

4 Apr 2012